Skip to main content
OpenTrials
Completed

NCT Number: NCT03852472

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hidradenitis Suppurativa Abscess Acne Inversa Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Clinical Site, Birmingham, Alabama, United States

Loading trial locations.

About this study

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 study in subjects with moderate to severe Hidradenitis Suppurativa.

The study is multicenter and will consist of three subject groups. Subjects will be randomized 1:1:1 to a treatment of 10mg avacopan twice daily, 30 mg avacopan twice daily or placebo twice daily for 12 weeks.

Following the 12 weeks double-blind treatment period, subjects on placebo will be re-randomized 1:1 to receive 10 mg or 30 mg avacopan twice daily for additional 24 weeks. Subjects treated with avacopan will continue to receive the same dose (either 10 mg or 30 mg twice daily) for additional 24 weeks.

Subjects will be on study treatment for 36 weeks and will be followed for 44 weeks for assessment of safety and efficacy.

Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Primary efficacy analysis will be at 12 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years of age
  • Clinical diagnosis of HS (Hurley Stage II or III), confirmed by a dermatologist, for at least 6 months prior to Screening
  • HS lesions are present in at least 2 distinct anatomic areas
  • Inadequate or loss of response to a systemic course of antibiotics typically of at least 90 days
  • Must have at least 5 inflammatory nodules or abscesses at screening
  • Use adequate birth control for subject and partners of child bearing potential
  • Willing and able to give written Informed Consent

Exclusion criteria

  • Pregnant or breast-feeding
  • Any other skin disease that may interfere with the assessment of HS
  • Rapidly progressive, expanding HS within 30 days prior to screening
  • More than 20 draining fistulae at screening
  • Any anti-TNF-α treatment for HS or for other conditions prior to Day 1 visit will be prohibited. Exception: Subjects who were previously treated with an anti-TNF-α drug and discontinued treatment >12 weeks prior to Day 1 visit are allowed for enrollment
  • Systemic antibiotics are generally excluded
  • Topical antibiotics use within 14 days prior to Day 1 is excluded
  • Have started a topical prescription medicine for HS within 14 days prior to screening
  • A systemic medicine for HS, including biologics and other systemic therapies
  • Have received within 14 days prior to Day 1 visit or is expected to require oral or transdermal opioid analgesics (except for tramadol) for any reason

Treatment and study plan

Avacopan

Drug

Active treatment

Other names: CCX168

Placebo

Other

Placebo

Primary outcomes

  1. Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.

    Time frame: Baseline to Week 12

    The percentage of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 in the ITT1 population using the NRI-CMH Test. A response was defined as a reduction of at least 50 in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count compared with baseline.

    The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

    NRI- non-responder imputation; CMH- Cochran-Mantel-Haenszel. Percentage values have been reported as opposed to proportion values to allow for statistical analyses.

Secondary outcomes

  1. Change From Baseline in Total AN Count at Week 12

    Time frame: Baseline to Week 12

    The Change from Baseline in total AN (abscess and inflammatory nodule) count at Week 12 using MMRM and OC in the ITT1 population.

    The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

    MMRM - mixed effects model for repeated measures; OC- observed case

  2. Number of Responders Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in the Subject's Global Assessment of Skin Pain (NRS30) in Subjects With a Baseline NRS of at Least 3, Evaluated at Week 12

    Time frame: Baseline to Week 12

    NRS30 = The number of responders achieving at least 30% reduction and at least 1 unit reduction from baseline in the subject's global assessment of skin pain score. Percentage is based on the number of subjects with a baseline pain score of at least 3 in each treatment group.

    Weekly averages of daily pain will be calculated based on subjects' daily diary recording of the worst pain experienced in the previous 24 hours.

    The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

    NRI- non-responder imputation

  3. Area Under the Curve From Time 0-3hrs (AUC 0-3hrs) of Metabolite M1 Plasma Concentration on Day 1

    Time frame: Day 1

    The Area under the curve from Time 0-3hrs (AUC 0-3hrs) of Metabolite M1 plasma concentration on Day 1 in the PK population.

    PK- pharmacokinetics

  4. Number of Responders With Baseline Hurley Stage II Who Achieved an AN Count of 0, 1, or 2 at Week 12

    Time frame: Baseline and Week 12

    The number of responders With Baseline Hurley Stage II Who Achieved an Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12 using the NRI-CMH Test in the ITT1 population. Hurley Stage II disease is defined as having 1 or more widely separated recurrent abscesses with tract formation and scars.

    The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

  5. Change of IHS4 Score Relative to Baseline at Week 12.

    Time frame: Baseline and Week 12

    The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

    IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS.

    IHS4- International HS Severity Scoring System

  6. Change From Baseline in Inflammatory Nodule Count at Week 12

    Time frame: Baseline and Week 12

    A reduction in AN signifies improvement. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

  7. Change From Baseline in Abscess Count at Week 12

    Time frame: Baseline and Week 12

    A reduction in abscess count signifies improvement. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

  8. Change From Baseline in Draining Fistula Count at Week 12

    Time frame: Baseline and Week 2, Week 4, Week 8 and Week 12

    The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

  9. Change From Baseline to Week 12 in the Modified Sartorius Score to Quantify the Severity Change of HS

    Time frame: Baseline and Week 2, Week 4, Week 8 and Week 12

    Twelve body areas will be evaluated to calculate the Sartorius and modified Sartorius scores: left and right axillae, left and right inframammary areas, intermammary area, left and right buttocks, left and right inguinocrural folds, perianal area, perineal area, and other. The presence of nodules, abscesses, fistulae, scars, and other findings will be recorded. The longest distance between two lesions and whether lesions are separated by normal skin is recorded. A score of 4 indicates the least severe disease, and higher scores indicate increasingly severe disease. There is no upper limit in the score. The ITT1 population was defined as all subjects who were randomized at baseline and received at least 1 dose of investigational product during period 1.

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Feb 25, 2019
Registry last updated
Mar 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.